THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...
MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...
The trial evaluates THIO, a telomere-targeting agent, in combination with Regeneron (NASDAQ:REGN)'s cemiplimab, an immune checkpoint inhibitor, in patients who have not responded to at least two ...
MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...
The National Anti-Violence and Sexual Harassment Helpline received about 11,600 calls in 2023, up from 10,800 in 2022. Read ...
A semi-detached house on Coldstream Avenue, located in the prestigious Frankel Estate in the East, has been listed for $12.3 ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
The setting up of Lionheart Advocates aligns with recent efforts by the government to curb the abuse of court processes.
New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results